Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Dermatology
Published in: BMC Dermatology 1/2018

Open Access 01-12-2018 | Study protocol

Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial

Authors: Mathias Tiedemann Svendsen, Flemming Andersen, Kirsten Hammond Andersen, Klaus Ejner Andersen

Published in: BMC Dermatology | Issue 1/2018

Login to get access

Abstract

Background

Topical corticosteroid or corticosteroid/calcipotriol preparations are recommended first-line topical treatments of psoriasis, but a main cause for the lack of efficacy of topical treatments is considered low rates of adherence to topical drugs. Patient support by the use of applications (apps) for smartphones is suggested to improve medical adherence.

Methods/design

Design: An investigator-initiated, single-center, single-blind, parallel-group, phase-4 clinical superiority randomized controlled trial (RCT). Participants: 134 patients 18 to 75 years of age with mild-to-moderate psoriasis, who are capable of reading English language, own a smartphone, and are candidates for the study drug calcipotriol and betamethasone dipropionate (Cal/BD) cutaneous foam once daily prn (pro re nata). Intervention: A 28-day adherence-supporting app providing compulsory daily treatment reminders that pop-up on the smartphone screen with a short alert sound. The app synchronizes through Bluetooth® to an electronic monitor (EM) attached to the medication canister. The EM contains a chip registering the amount of foam, day and time the patient use the foam dispenser. The information is displayed in a diary that shows the amount of Cal/BD cutaneous foam used and the number of applied treatment sessions. The app has an optional diary with the patient’s rating of symptoms. Non-intervention: Use of Cal/BD cutaneous foam and EM without the app. All participants are prescribed Cal/BD cutaneous foam prn for the entire study period.
Primary outcome obtained in week 4: rates of adherence measured by patient report, weight of medication canisters, and number of treatment sessions measured by the EM. Secondary outcomes obtained at baseline, weeks 4, 8, and 26: Lattice System Physician’s Global Assessment (LS-PGA) and Dermatology Quality of Life Index (DLQI).

Discussion

This trial tests of whether an app can improve rates of adherence to a topical antipsoriatic drug. If the app improves rates of adherence and reduces the burden of psoriasis in a clinically significant way, the app could easily be implemented as a standard routine of care in the clinic.

Trial registration

NCT02858713, registered on August 3, 2016. EudraCT number 2016–002143-42.
Appendix
Available only for authorised users
Literature
1.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J invest dermatol. 2013;133(2):377–85.CrossRefPubMed
2.
Stein Gold L, Corvari L. The roles of safety and compliance in determining effectiveness of topical therapy for psoriasis. Cutis. 2007;79(1 Suppl 2):32–8.PubMed
3.
Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;3:CD005028.
4.
Storm A, Andersen SE, Benfeldt E, Serup J. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol. 2008;59(1):27–33.CrossRefPubMed
5.
Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol. 2002;54(2):212–20.CrossRefPubMedPubMedCentral
6.
Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, Agoritsas T, Mistry N, Iorio A, Jack S, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:Cd000011.
7.
8.
Svendsen MT, Andersen F, Hansen J, Johannessen H, Andersen KE. Medical adherence to topical corticosteroid preparations prescribed for psoriasis: a systematic review. J dermatol treat. 2017;28(1):32–9.CrossRef
9.
Svendsen MT, Jeyabalan J, Andersen KE, Andersen F, Johannessen H. Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review. J dermatol treat. 2017;28(5):374–83.CrossRef
10.
Brown KK, Rehmus WE, Kimball AB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607–13.CrossRefPubMed
11.
Feldman SR. Disease burden and treatment adherence in psoriasis patients. Cutis. 2013;92(5):258–63.PubMed
12.
Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J dermatol treat. 2013;24(1):64–9.CrossRef
13.
Saeki H, Imafuku S, Abe M, Shintani Y, Onozuka D, Hagihara A, Katoh N, Murota H, Takeuchi S, Sugaya M, et al. Poor adherence to medication as assessed by the Morisky medication adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patients. J Dermatol. 2015;42(4):367–72.CrossRefPubMed
14.
Burroni AG, Fassino M, Torti A, Visentin E. How do disease perception, treatment features, and dermatologist-patient relationship impact on patients assuming topical treatment? An Italian survey. Patient Relat Outcome Meas. 2015;6:9–17.PubMedPubMedCentral
15.
Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408–14.CrossRefPubMed
16.
Storm A, Benfeldt E, Andersen SE, Serup J. A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol. 2008;59(6):975–80.CrossRefPubMed
17.
Ersser SJ, Cowdell FC, Latter SM, Healy E. Self-management experiences in adults with mild-moderate psoriasis: an exploratory study and implications for improved support. Br J Dermatol. 2010;163(5):1044–9.CrossRefPubMed
18.
Bewley A, Burrage DM, Ersser SJ, Hansen M, Ward C. Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. J Eur Acad Dermatol Venereol: JEADV. 2014;28(6):763–70.CrossRefPubMed
19.
Svedbom A, Dalen J, Mamolo C, Cappelleri J, Petersson I, Ståhle M. Treatment patterns with topicals, traditional systemics and biologics in psoriasis–a Swedish database analysis. J Eur Acad Dermatol Venereol. 2015;29(2):215–23.CrossRefPubMed
20.
de Korte J, Van Onselen J, Kownacki S, Sprangers MA, Bos JD. Quality of care in patients with psoriasis: an initial clinical study of an international disease management programme. J Eur Acad Dermatol Venereol. 2005;19(1):35–41.CrossRefPubMed
21.
Alinia H, Moradi Tuchayi S, Smith JA, Richardson IM, Bahrami N, Jaros SC, Sandoval LF, Farhangian ME, Anderson KL, Huang KE, et al. Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759–64.CrossRefPubMed
22.
Saeki H, Watanabe A, Tada Y, Kakinuma T, Komine M, Ihn H, Asahina A, Etoh T, Kitanaka S, Sato U, et al. Juvenile pustular psoriasis associated with steroid withdrawal syndrome due to topical corticosteroid. J Dermatol. 2008;35(9):601–3.CrossRefPubMed
23.
WHO: Atlas of eHealth country profiles: the use of eHealth in support of universal health coverage: based on the findings of the third global survey on eHealth 2015. Geneva, Switzerland: World Health Organization 2016.
24.
Yetisen AK, Martinez-Hurtado J, da Cruz Vasconcellos F, Simsekler ME, Akram MS, Lowe CR. The regulation of mobile medical applications. Lab Chip. 2014;14(5):833–40.CrossRefPubMed
25.
26.
Balato N, Megna M, Di Costanzo L, Balato A, Ayala F. Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis. Br J Dermatol. 2013;168(1):201–5.CrossRefPubMed
27.
Thaler RH, Sunstein CR. Nudge: improving decisions about health, wealth, and happiness revised and expanded edition. New York: Penguin; 2009.
28.
Snyder A, Taheri A. Dealing with Forgetfullness. In: Davis SA, editor. Adherence in dermatology. Switzerland: Springer international publishing; 2016. p. 163–70.
29.
30.
Balkrishnan R, Carroll CL, Camacho FT, Feldman SR. Electronic monitoring of medication adherence in skin disease: results of a pilot study. J Am Acad Dermatol. 2003;49(4):651–4.CrossRefPubMed
31.
Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, Herdman M, Firth P, Hotchkiss K. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: psoriasis area and severity index, Physician's global assessment and lattice system Physician's global assessment. Br J Dermatol. 2006;155(4):707–13.CrossRefPubMed
32.
Chow C, Simpson MJ, Luger TA, Chubb H, Ellis CN. Comparison of three methods for measuring psoriasis severity in clinical studies (part 1 of 2): change during therapy in psoriasis area and severity index, static Physician's global assessment and lattice system Physician's global assessment. J Eur Acad Dermatol Venereol. 2015;29(7):1406–14.CrossRefPubMed
33.
Simpson MJ, Chow C, Morgenstern H, Luger TA, Ellis CN. Comparison of three methods for measuring psoriasis severity in clinical studies (part 2 of 2): use of quality of life to assess construct validity of the lattice system Physician's global assessment, psoriasis area and severity index and static Physician's global assessment. J Eur Acad Dermatol Venereol. 2015;29(7):1415–20.CrossRefPubMed
34.
Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system Physician's global assessment. J Am Acad Dermatol. 2004;51(4):563–9.CrossRefPubMed
35.
Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology life quality index: data from Danish inpatients and outpatients. Acta Derm Venereol. 2000;80(4):272–6.CrossRefPubMed
36.
37.
Queille-Roussel C, Clonier F, Olesen M. Short-contact treatment with calcipotriene plus betamethasone dipropionate topical suspension in a psoriasis plaque test model. J Am Acad Dermatol. 2014;1:AB190.
38.
Koo J, Tyring S, Werschler WP, Bruce S, Olesen M, Villumsen J, Bagel J. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - a randomized phase II study. J dermatol treat. 2016;27(2):120–7.CrossRef
39.
Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Osterdal ML, Stein Gold L. Efficacy and safety of Calcipotriene plus Betamethasone Dipropionate aerosol foam in patients with psoriasis Vulgaris--a randomized phase III study (PSO-FAST). J Drugs Dermatol. 2015;14(12):1468–77.PubMed
40.
41.
42.
Krejci-Manwaring J, Tusa MG, Carroll C, Camacho F, Kaur M, Carr D, Fleischer AB Jr, Balkrishnan R, Feldman SR. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol. 2007;56(2):211–6.CrossRefPubMed
43.
Yentzer BA, Alikhan A, Teuschler H, Williams LL, Tusa M, Fleischer AB Jr, Kaur M, Balkrishnan R, Feldman SR. An exploratory study of adherence to topical benzoyl peroxide in patients with acne vulgaris. J Am Acad Dermatol. 2009;60(5):879–80.CrossRefPubMed
44.
Metadata
Title
Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial
Authors
Mathias Tiedemann Svendsen
Flemming Andersen
Kirsten Hammond Andersen
Klaus Ejner Andersen
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Dermatology / Issue 1/2018
Electronic ISSN: 1471-5945
DOI
https://doi.org/10.1186/s12895-018-0071-3

Other articles of this Issue 1/2018

BMC Dermatology 1/2018 Go to the issue

Research article

Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India)

Case report

Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report

Research article

Exploratory study of the reproducibility of the SCore for INtrinsic and EXtrinsic skin aging (SCINEXA) scale in “Ruta Escondida de la Mitad del Mundo”, Ecuador, 2017

Case report

A novel PLEC nonsense homozygous mutation (c.7159G > T; p.Glu2387*) causes epidermolysis bullosa simplex with muscular dystrophy and diffuse alopecia: a case report

Research article

Cost and effectiveness of prescribing emollient therapy for atopic eczema in UK primary care in children and adults: a large retrospective analysis of the Clinical Practice Research Datalink

Research article

Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database